Summary of Phio Pharmaceuticals Conference Call Company Overview - **Company**: Phio Pharmaceuticals (NasdaqCM:PHIO) - **Industry**: Clinical-stage immuno-oncology focused on treating skin cancers - **Technology**: INTASYL, a proprietary short interfering gene silencing technology aimed at enhancing T-cell effectiveness against tumors [2][3] Market Opportunity - **Target Disease**: Cutaneous squamous cell carcinoma (CSCC) - **Market Size**: Estimated addressable market value of approximately $20 billion, with 1.8 million annual diagnoses [3][24] - **Mortality Rate**: CSCC has an annual death toll approximately twice that of melanoma [3] Technology and Development - **INTASYL Mechanism**: Targets and silences the PD-1 gene, allowing T-cells to attack tumors more effectively [6][10] - **Clinical Trials**: Recently completed Phase 1b trial for PH-762, showing an 85% pathological response rate in the final cohort [15][16] - **Safety Profile**: No immune-related or treatment-related toxicities reported across five dose-escalating cohorts, despite a 20-fold increase in dose concentration [16][25] Competitive Landscape - **Current Treatments**: Existing monoclonal antibodies like Keytruda and Libtayo have total clearance rates of approximately 17% and 11% respectively for advanced skin cancers [26] - **Unique Selling Proposition**: PH-762 offers a direct injection method, potentially reducing systemic side effects and improving patient convenience [16][18] Future Plans - **Next Steps**: Planning to design the next clinical study and seek FDA guidance in Q2 2026, with hopes to commence the next trial in Q1 2027 [18][28] - **Additional Compound**: PH-894, targeting the BRD4 gene, is also in development and expected to enter IND stage following FDA feedback [19][22] Financials - **Cash Runway**: Sufficient funds to support operations into the first half of 2027 [22] - **Shares Outstanding**: 11.6 million common shares, with additional warrants exercisable at $2.05 [22] Leadership and Infrastructure - **Team Composition**: Ultra-lean structure with only eight employees and four subject matter experts, all with extensive experience in drug development [4][23] - **Intellectual Property**: 54 patents issued covering various aspects of the technology, ensuring a strong competitive position [8][24] Conclusion - Phio Pharmaceuticals is positioned to address a significant unmet need in the treatment of cutaneous squamous cell carcinoma with its innovative INTASYL technology, demonstrating promising clinical results and a favorable safety profile, while also planning for future growth and development in the oncology space [24][35]